Understanding the influence and mechanisms by which purinergic receptors control the release of noradrenaline evoked by NMDARs in the brain cortex may open new lines of intervention in CNS pathologies that course with a dysregulation of noradrenergic transmission, such as in mood disorders, cognition and the progression of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease [24,25] or dysregulation of glutamatergic transmission, which occurs in ischemia, epilepsy, mood disorders and neurodegenerative diseases [26,27,28,29]. Here, P2RY1 is linked to neurodegenerative disease.